Replimune Group (NASDAQ:REPL) Given New $18.00 Price Target at BMO Capital Markets

Replimune Group (NASDAQ:REPL) had its price target upped by BMO Capital Markets from $14.00 to $18.00 in a research report released on Friday,Benzinga reports. BMO Capital Markets currently has an outperform rating on the stock.

Other equities research analysts also recently issued research reports about the company. Roth Capital upgraded Replimune Group to a “strong-buy” rating in a research report on Tuesday, August 27th. JPMorgan Chase & Co. raised their price target on Replimune Group from $14.00 to $17.00 and gave the company an “overweight” rating in a research report on Tuesday, September 24th. Roth Mkm initiated coverage on Replimune Group in a research report on Tuesday, August 27th. They set a “buy” rating and a $17.00 price target on the stock. Finally, HC Wainwright restated a “buy” rating and set a $17.00 price target on shares of Replimune Group in a research report on Friday. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Replimune Group currently has a consensus rating of “Buy” and a consensus price target of $17.00.

Replimune Group Trading Up 35.1 %

NASDAQ:REPL opened at $14.93 on Friday. Replimune Group has a 52-week low of $4.92 and a 52-week high of $17.00. The stock has a fifty day moving average of $11.51 and a 200 day moving average of $9.67. The company has a debt-to-equity ratio of 0.18, a current ratio of 10.11 and a quick ratio of 10.11.

Replimune Group (NASDAQ:REPL) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.68) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.07. On average, equities analysts forecast that Replimune Group will post -3.02 EPS for the current fiscal year.

Insider Activity

In other news, insider Konstantinos Xynos sold 7,246 shares of the business’s stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $10.78, for a total value of $78,111.88. Following the completion of the sale, the insider now owns 109,885 shares of the company’s stock, valued at approximately $1,184,560.30. The trade was a 6.19 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 8.80% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Baker BROS. Advisors LP raised its position in Replimune Group by 10.0% during the 3rd quarter. Baker BROS. Advisors LP now owns 11,045,336 shares of the company’s stock valued at $121,057,000 after purchasing an additional 1,000,000 shares during the last quarter. Price T Rowe Associates Inc. MD grew its holdings in shares of Replimune Group by 12.0% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 6,548,930 shares of the company’s stock worth $53,505,000 after acquiring an additional 699,679 shares during the period. Millennium Management LLC grew its holdings in shares of Replimune Group by 575.1% during the 2nd quarter. Millennium Management LLC now owns 3,118,035 shares of the company’s stock worth $28,062,000 after acquiring an additional 2,656,173 shares during the period. Braidwell LP grew its holdings in shares of Replimune Group by 203.0% during the 3rd quarter. Braidwell LP now owns 3,070,837 shares of the company’s stock worth $33,656,000 after acquiring an additional 2,057,460 shares during the period. Finally, Vanguard Group Inc. grew its holdings in shares of Replimune Group by 1.2% during the 1st quarter. Vanguard Group Inc. now owns 2,770,328 shares of the company’s stock worth $22,634,000 after acquiring an additional 32,555 shares during the period. Institutional investors own 92.53% of the company’s stock.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.